An Update on Therapy Options for Early Alzheimer’s Disease
This presentation will discuss newer agents being used in the treatment of Alzheimer’s disease. Significant controversy exists surrounding the use of these medications, and the data behind them. This presentation will walk through this data and allow attendees to feel more comfortable evaluating these treatment options for patients.
Target Audience
This activity is intended for pharmacists and pharmacy technicians.
Learning Objectives
Pharmacists learning objectives
At the conclusion of this activity, pharmacists should be able to:
- Summarize the pathophysiology of Alzheimer’s disease and outline historical treatment options.
- Evaluate the literature of late-stage anti-amyloid monoclonal antibodies.
- Discuss the potential impact of new medications in the treatment of Alzheimer’s Disease.
Pharmacy technician learning objectives
At the conclusion of this activity, pharmacy technicians should be able to:
- Discuss the potential impact of new medications in the treatment of Alzheimer’s Disease.
Additional Information
Attachment | Size |
---|---|
Helpful Tips for Users - Vizient CE System.pdf | 134.81 KB |
Faculty
Mitchell Blewett, PharmD, MS, BCPS
Oncology Pharmacy Manager
Taussig Cancer Institute Cleveland Clinic
Planning committee
Gretchen Brummel, PharmD, BCPS
Pharmacy Executive Director
Vizient Center for Pharmacy Practice Excellence
Vizient, Inc.
Jackie Stokes, BBA
Manager, Pharmacy Program
Vizient, Inc.
Identification, Mitigation, and Disclosure of Relevant Financial Relationships
As an accredited provider of continuing education, Vizient, Inc. is dedicated to ensuring this activity presents learners with only accurate, balanced, scientifically justified recommendations, and is free from promotion, marketing, and commercial bias. In accordance with The Standards for Integrity and Independence in Accredited Continuing Education, all planners, faculty, and others in control of the educational content have disclosed the absence or existence of all financial relationships (of any dollar amount) with ineligible companies within the past 24 months.
It is Vizient’s policy that owners and employees of ineligible companies, and any individuals who refuse to disclose the absence or existence of financial relationships with any ineligible companies are disqualified from participating as planners or faculty.
Disclosure of Financial Relationships:
Absence of Relevant Financial Relationships
Vizient, Inc., Jointly Accredited for Interprofessional Continuing Education, defines companies to be ineligible as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
An individual is considered to have a relevant financial relationship if the educational content an individual can control is related to the business lines or products of the ineligible company.
No one in a position to control the content of this educational activity have relevant financial relationships with ineligible companies.
Statement of content validity
Vizient, Inc. educational activities are intended to assist healthcare teams advance their professional responsibilities in accordance with the definition of continuing education. It is the policy of Vizient, Inc. to review and ensure that all content and recommendations for patient care within accredited CE is evidenced-based, based on current science and clinical reasoning while ensuring the content is fair and balanced. All recommendations must conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation. Vizient, Inc. does not permit accredited continuing education if it advocates for unscientific approaches to diagnosis or therapy, or if the education promotes recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.
FDA off-label/unapproved usage
Faculty/Presenters are required to identify any new and evolving topics for which there is a lower/absence of evidence base. This is to ensure that our content does not advocate for, or promote, practices that are not, or not yet adequately based on current science, evidence, and clinical reasoning. Faculty/Presenters are required to disclose any discussion of (1) off-label/unapproved or investigational uses of FDA approved commercial products or devices and/or (2) products or devices not yet approved in the United States.
Disclaimer: The education provided through this activity is for continuing education purposes only. The views and opinions expressed in this activity are those of the faculty/presenters and do not necessarily reflect the views of Vizient, Inc.
Joint Accreditation Statement:
In support of improving patient care, Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Designation Statement(s):
PHARMACY
Vizient, Inc. designates this activity for a maximum of 1.0 ACPE credit hours.
Universal Activity Number: JA0006103-0000-23-238-L01-P
Universal Activity Number: JA0006103-0000-23-238-L01-T
OTHER
Vizient, Inc. will award all other healthcare professionals who successfully complete the activity a Certificate of Participation. Various state license boards and credentialing bodies accept certificates of participation from accredited CE activities to meet CE requirements for license renewals and re- certification. It is the responsibility of the participant to contact their state licensing board and/or certifying body for verification on credit eligibility reciprocity.
Available Credit
- 1.00 ACPE Pharmacist
- 1.00 ACPE Pharmacy Technician
- 1.00 General CE - Attendance